Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502704 | 1.00 | KAT2B (0.58) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL10622798 | 0.91 | KAT2B (0.72) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL8107611 | 0.90 | MAPT (0.60) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL2228520 | 0.89 | KAT2B (0.66) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL30413993 | 0.88 | KAT2B (0.64) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL2228171 | 0.88 | KAT2B (0.64) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL17923845 | 0.88 | KAT2B (0.64) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL4557828 | 0.88 | KAT2B (0.64) | KAT2BMAPTPOLBPKMKDM4E | |
| Hydrochloric Acid SCHEMBL4699216 | 0.87 | KAT2B (0.65) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL8147273 | 0.87 | MAPT (0.65) | KAT2BMAPTPOLBPKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | URTESTE S.A. (PL) | 2026-04-09 | — | — | US | claimed |
| US-20250376711-A1 | COMPOUND-DIAGNOSTIC MARKER FOR UTERINE BODY CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF UTERINE BODY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF UTERINE BODY CANCER | URTESTE S.A. (PL) | 2025-12-11 | — | — | US | claimed |
| EP-4649167-A2 | COMPOUND - DIAGNOSTIC MARKER FOR BILIARY TRACT CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF BILIARY TRACT CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF BILIARY TRACT CANCER | Urteste S.A. (PL) | 2025-11-19 | — | — | EP | claimed |
| WO-2025216642-A1 | ENZYMATIC ACTIVITY BASED METHOD AND MARKER FOR THE DIAGNOSIS OF BRAIN TUMOUR | URTESTE S.A. (PL) | 2025-10-16 | — | — | WO | claimed |
| US-20250270617-A1 | Compound - diagnostic marker for kidney cancer, method for detecting enzymatic activity, method for diagnosis of kidney cancer, kit comprising the compound, uses of the compound and method for the treatment of kidney cancer | URTESTE S.A. (PL) | 2025-08-28 | — | — | US | claimed |
| EP-4594335-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | Urteste S.A. (PL) | 2025-08-06 | — | — | EP | claimed |
| US-20250206777-A1 | COMPOUND - DIAGNOSTIC MARKER FOR INTESTINAL CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF INTESTINAL CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF INTESTINAL CANCER | URTESTE S.A. (PL) | 2025-06-26 | — | — | US | claimed |
| CN-119998307-A | Compound-ovarian cancer diagnostic markers, method for detecting enzymatic activity, method for diagnosing ovarian cancer, kit comprising said compound, use of said compound and method for treating ovarian cancer | 尔特斯特公司 | 2025-05-13 | — | — | CN | claimed |
| EP-4547686-A1 | COMPOUND-DIAGNOSTIC MARKER FOR UTERINE BODY CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF UTERINE BODY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF UTERINE BODY CANCER | Urteste S.A. (PL) | 2025-05-07 | — | — | EP | claimed |
| EP-4511383-A1 | COMPOUND - DIAGNOSTIC MARKER FOR KIDNEY CANCER, METHOD LOR DETECTING ENZYMATICACTIVITY, METHOD FOR DIAGNOSIS OF KIDNEY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF KIDNEY CANCER | Urteste S.A. (PL) | 2025-02-26 | — | — | EP | claimed |
| WO-2023204721-A1 | COMPOUND - DIAGNOSTIC MARKER FOR KIDNEY CANCER, METHOD LOR DETECTING ENZYMATICACTIVITY, METHOD FOR DIAGNOSIS OF KIDNEY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF KIDNEY CANCER | URTESTE S.A. (PL) | 2023-10-26 | — | — | WO | claimed |
| WO-2023191647-A1 | COMPOUND - DIAGNOSTIC MARKER FOR INTESTINAL CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF INTESTINAL CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF INTESTINAL CANCER | URTESTE S.A. (PL) | 2023-10-05 | — | — | WO | claimed |
| US-20230204587-A1 | NOVEL DIAGNOSTIC MARKER FOR PROSTATE CANCER | URTESTE S.A. (PL) | 2023-06-29 | — | — | US | claimed |
| WO-2023106945-A1 | FRET ENZYMATIC SUBSTRATE AND USES THEREOF IN LUNG CANCER. | URTESTE S.A. (PL) | 2023-06-15 | — | — | WO | claimed |
| WO-2023080800-A1 | FRET ENZYMATIC SUBSTRATE AND USES THEREOF IN LIVER CANCER. | URTESTE S.A. (PL) | 2023-05-11 | — | — | WO | claimed |
| CN-115989413-A | Novel diagnostic marker for prostate cancer | 尔特斯特公司 | 2023-04-18 | — | — | CN | claimed |
| EP-4162276-A1 | NOVEL DIAGNOSTIC MARKER FOR PROSTATE CANCER | Urteste S.A. (PL) | 2023-04-12 | — | — | EP | claimed |
| US-20220251625-A1 | NOVEL DIAGNOSTIC MARKER FOR PANCREATIC CANCER | URTESTE S.A. (PL) | 2022-08-11 | — | — | US | claimed |
| EP-3987050-A1 | NOVEL DIAGNOSTIC MARKER FOR PANCREATIC CANCER | Urteste S.A. (PL) | 2022-04-27 | — | — | EP | claimed |
| CN-114096555-A | Novel pancreatic cancer diagnostic marker | 尔特斯特公司 | 2022-02-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | DNPEP, ANPEP, CA9 | KAT2B 1515/4885MAPT 4823/4885POLB 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.